ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0746

The Association Between Sonographic Imaging Phenotype and Response to Treatment in Patients with Psoriatic Arthritis
Abstract Number: 2318

The Association Between Systemic Lupus Erythematosus (SLE) and Bone Mineral Density (BMD) Polygenic Risk Scores with Lumbar Spine BMD Z-score: A Retrospective Cohort Study
Abstract Number: 1981

The Association Between X-ray Progression and Clinical Outcomes in Patients with Hand Osteoarthritis with 5-year Follow-up
Abstract Number: 1401

The Association of 3VAS/4VAS and DAPSA with Radiographic Progression in Early PsA
Abstract Number: 1815

The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register
Abstract Number: 0318

The Association of CT-Detected Intra-Articular Mineralization with MRI-Detected Effusion-Synovitis and Hoffa’s Synovitis in Knee OA: The Multicenter Osteoarthritis Study
Abstract Number: 1543

The Association of Frailty with Outcomes in Patients with Vasculitis
Abstract Number: 0710

The Association of IgA Vasculitis and Malignancy in Adults: A Systematic Review
Abstract Number: 1193

The Association of Peak Forces and Loading Rates During Walking with MRI-Based Structural Worsening of the Knee: The Multicenter Osteoarthritis Study
Abstract Number: 1237

The Associations Between Depressive Symptoms and Executive Function and Academic Outcomes in Children with SLE
Abstract Number: 1838

The Burden of Dysautonomia in Patients Suffering from Pathologies Associated with Generalized Joint Hypermobility
Abstract Number: 1542

The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study
Abstract Number: 0966

The Burden of Oligoarticular Psoriatic Arthritis in the United States
Abstract Number: 0894

The Cellular and Spatial Type I Interferon Response Following Skin Exposure to Ultraviolet Light
Abstract Number: 0538

The Challenge of Identifying Difficult-To-Treat Axial Spondyloarthritis in Clinical Practice: Results from La Paz-SpA Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].